Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2009
Reporting Period: The filing primarily addresses a material event occurring on March 2, 2009, and references financial results for the fourth quarter and fiscal year ended December 31, 2008, which were announced via a press release on March 3, 2009.
Key Financial Metrics and Transaction Details
This filing details a specific transaction rather than providing a full set of financial statements. Key financial figures relate to the termination of a distribution agreement:
- Termination Payment: Euro 2,000,000 in cash to Edwards Lifesciences AG for early termination of the Distribution Agreement.
- Asset Purchase: Euro 250,000 in cash for related assets, including customer lists and assignable contracts.
- Inventory Repurchase: Biomateriali S.r.l. agreed to repurchase most of Edwards' AlboGraft inventory at Edwards' net purchase price, subject to a discount for older inventory.
- Exchange Rate: 1 Euro = 1.2672 U.S. Dollars (as of March 2, 2009).
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the company. These metrics are referenced as being contained in the attached press release (Exhibit 99.1) but are not detailed in the body of this 8-K.
Material Changes Versus Prior Period
The primary material change is the termination of the Supply and Distribution Agreement dated January 1, 2005, between LeMaitre's subsidiary, Biomateriali S.r.l., and Edwards Lifesciences AG. Under the original agreement, Edwards was the exclusive distributor of the AlboGraft Vascular Graft in Europe and certain international markets through December 31, 2011. The new Termination Agreements end this exclusive relationship early, effective upon the closing of the transaction.
Guidance, Outlook, and Management Commentary
Transaction Closing: The transaction is scheduled to close on March 27, 2009, subject to customary closing conditions.
Transition Services: Edwards will provide sales and marketing cooperation, detailed customer information, and continue selling the AlboGraft Vascular Graft in certain markets/customers for Biomateriali's benefit in exchange for a service fee.
Outlook: The filing does not contain specific forward-looking guidance or management commentary regarding future financial performance beyond the details of the transaction and the reference to the March 3, 2009 press release.
Risks/Contingencies: The closing is contingent on customary conditions. Both parties have agreed to indemnification for losses arising from breaches or misrepresentations under the Termination Agreements.
Important Facts for Investor Verification
- Verify the total cash outflow impact of the transaction (Euro 2.25 million plus inventory repurchase costs) against the company's current liquidity position.
- Review the attached press release (Exhibit 99.1) for the actual Q4 and full-year 2008 financial results, as they are not included in this text.
- Confirm the specific terms of the "service fee" for transition services and the discount applied to older inventory repurchases.
- Assess the strategic impact of terminating the exclusive distribution agreement with Edwards Lifesciences AG in Europe and international markets.
- Monitor the closing date of March 27, 2009, to ensure the transaction completes as scheduled.